Simplesa, a nutrition company established in 2013 after the amyotrophic lateral sclerosis (ALS) community showed its support for its metabolic supplement called the Deanna Protocol, or DP diet, has expanded the Deanna Protocol Bundle Pack choices for consumers. The Deanna Protocol is an all-natural metabolic program developed by Dr. Vincent Tedone, a…
Baylor College of Medicine and the Belgium-based biopharmaceutical company UCB announced that they have entered into a strategic partnership, led by Baylor Professor Huda Zoghbi, to discover new medicines to better treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The research alliance is in keeping UCB’s commitment to accelerating the discovery…
The Target ALS Foundation, a collaborative research consortium, received a $5 million matching-gift donation from Biogen to help establish the foundation’s new Industry Fund for ALS Research, supporting a network of private-public research laboratories working to develop effective treatments and, ideally, a cure for amyotrophic lateral sclerosis (ALS). “Biogen is deeply committed to ALS…
The ALS Association (ALSA)Â recently held its sixth annual Heroes Luncheon, honoring outstanding people with amyotrophic lateral sclerosis (ALS) whose efforts have made significant contributions to the ALS community. The four honorees at the Feb. 5 luncheon in Atlanta, Georgia, were: Nanci Ryder, a Hollywood publicist and co-founder of…
The ALS Association announced that it has awarded a total of $755,855 in financial grants supporting new clinical management projects to address unmet needs in amyotrophic lateral sclerosis (ALS) care. For this grant program, the ALS Association defined areas of priority research and invited experts to submit their proposals, according to a…
ProMIS Neurosciences announced that it has established Business (BAB) and Scientific (SAB) advisory boards to advance the company’s work. ProMIS is developing its first products focused on more effective treatments of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD). “Our number one goal is to create the appropriate precision therapeutics and companion diagnostics…
Oregon State University researchers were able to stop the progression of amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) for nearly two years in a specific type of mouse model. The treatment allowed the animals to live for 650 days – 500 days longer than any other previous treatment has managed.
Researchers at the Institute for EthnoMedicine and the University of Miami Brain Endowment Bank have discovered that chronic exposure to an environmental toxin has the potential to increase the risk for neurodegenerative illnesses such as ALS and Alzheimer’s disease. The research paper, “Dietary exposure to an environmental toxin triggers neurofibrillary tangles and…
University of Kyoto researchers discovered that a protein associated with a gene involved in cancer suppression, the VHL protein, and a protein that rescues cells from hypoxia (low oxygen) conditions, cullin2, are both involved in ALS progression. This discovery can lead to the identification of therapeutic targets for ALS treatment. The…
Amylyx Pharmaceuticals, a company developing a innovative therapeutic for amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), recently announced that former Biogen CEO Walter Gilbert, Ph.D and Nobel Laureate, will join Amylyx’s board of directors. “Dr. Gilbert brings an enormous breadth of experience as a scientist, biotech founder,…
Get regular updates to your inbox.